Navigation Links
Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
Date:10/23/2008

ng those caused by MRSA, as well as community acquired pneumonia. Novexel's future clinical development with NXL103 is expected to focus on its potential to be used in hospitals as an oral agent for the treatment of infections caused by Gram positive organisms, including resistant pathogens such as MRSA. Currently, physicians have a very limited choice of anti-MRSA antibacterials when they wish to switch from intravenous (IV) to oral treatment, a key step prior to a patient being discharged from the hospital.

In the second quarter of 2008 sanofi-aventis elected not to exercise its option to develop and commercialise NXL103. Consequently, worldwide rights to the NXL103 programme are retained by Novexel.

Iain Buchanan, Novexel's CEO, commenting on the announcement said, "We are very pleased that the results from our first Phase II clinical trial with NXL103 are positive. The data from this trial confirm the efficacy of NXL103 in patients with mild to moderate CAP. Furthermore, the pre-clinical and clinical work that we have carried out to-date with NXL103 provides a compelling platform for Phase III development. We believe that with its potent activity against MRSA, NXL103 may offer physicians an important therapeutic option when they switch patients from IV to oral treatment prior to discharge from the hospital."

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel anti-bacterials designed to overcome the significant global problem of bacterial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $15bn in 2007 according to information derived from the IMS Midas(R) database.

Novexel currently has two novel antibacterials in Phase II clinical development. These are the in
'/>"/>

SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
2. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
3. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
4. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
5. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
6. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
7. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
8. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
9. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
10. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
11. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 LifeNet Health ... total hiring for 2015 to more than 160 people. ... increased demand for LifeNet Health,s innovative bio-implants, which are ... more patients to be served. It also is a ... industry. "The growth and success of LifeNet ...
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/ltwldz/surgicaloperating ... "Surgical/Operating Microscopes Market by Application & End User ... their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... to reach $806.6 million by 2020 from $402.2 ... from 2015 to 2020. , ,Major factors fueling ...
(Date:5/29/2015)... May 29, 2015  Haemonetics Corporation (NYSE: HAE ... Operating Officer, will present at the JMP Securities Life ... on June 23 rd , 2015 at 11:30am Eastern ... Davies, presentation live via webcast at: http://wsw.com/webcast/jmp27/hae ... HAE ) is a global healthcare company dedicated to ...
Breaking Medicine Technology:LifeNet Health to add more than 160 jobs in 2015 2Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2
... Dec. 13, 2010 The creators of the innovative Pill Timer, ... and a much needed medication management system to pediatric patients ... Broward General, in Fort Lauderdale, Florida. Representatives ... be onsite Wednesday, December 15, from 1-3 pm distributing the ...
... IRVINE, Calif., Dec. 13, 2010 Masimo ... that a new clinical study demonstrating the accuracy of ... presented last week at the American Association of ... in Las Vegas. The largest gathering of respiratory care ...
Cached Medicine Technology:Med Time Technology, Inc. Teams up with Give A Smile, Inc. to Provide Pill Timer™ Kits and Toys to Children and Parents at the Chris Evert Children's Hospital of Broward General 2New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 2New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 3New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 4New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 5New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 6
(Date:5/29/2015)... Shaila Jiwa, a physiotherapist from Burnaby ... stated in a new announcement that patients of urinary ... commonly seen as a tabooed topic to talk about ... like Shaila Jiwa try to encourage people to come ... is a condition that can be classified under two ...
(Date:5/29/2015)... 29, 2015 The Global Allopurinol ... study on the current state of the Allopurinol ... key statistics on the state of the industry ... direction for companies and individuals interested in the ... the industry including definitions, classifications, applications and industry ...
(Date:5/29/2015)... Mirada, CA (PRWEB) May 29, 2015 ... traumatic brain injuries with the help of their licensed ... mild traumatic brain injuries can lead to an extensive ... impairments; these effects can arise at any time after ... can be caused by any bump or jolt to ...
(Date:5/29/2015)... The annual aesthetic meeting, put on by ... in Montreal from May 14-19th. This global event sets ... around the world; dedicating itself exclusively to cosmetic medicine. ... plastic surgeons to attend this year’s meeting. , Among ... Vitenas was given the honor of sitting at the presenter’s ...
(Date:5/29/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 29, 2015 ... in the vulvar region and can cause significant physical, ... understands the major life altering disorder of Vulvodynia. The ... exclusion. At Women’s Excellence in Endometriosis, they realize that ... If a patient is experiencing any of these symptoms, ...
Breaking Medicine News(10 mins):Health News:Patients of Urinary Incontinence Should Not "Hide And Suffer," States Physiotherapist from Burnaby Physiotherapy Clinic 2Health News:Allopurinol Industry (Global, China) 2015 Research Analysis and 2020 Forecasts 2Health News:Healthpointe’s Los Angeles County Clinics Are Now Offering Treatment for Mild Traumatic Brain Injuries 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical ... ) focused on bringing the life saving ... pleased to announce that between February 15, 2009, and today, ... or 12 percent. This follows the announcement on Feb. ...
... CORPS, April 6 The United States Marine Corps ... 2009 when the city opens its doors to the ... activities throughout the Chicagoland area. "Established to recognize ... the cities from which they came, Marine Week also ...
... The nation’s most trusted distributor of plasma products, vaccines and critical-care ... well as new Fluzone® return policy. , ... (Vocus) ... vaccine distribution marketplace, FFF Enterprises, Inc., is pleased to ...
... stumbled across a cure for high blood pressure and heart disease during ... ... 2009 -- The Elmore Oil Company, a Bendigo based company who manufactures ... a double blind placebo controlled trial for their flagship product, Elmore Oil., ...
... 5 Parents can have a tremendous impact on ... learning potential. By using techniques that stimulate the brain ... enhance the child,s awareness of its environment and comprehensive ... Kang announces the launch of Spotlight Baby. Kang says, ...
... Helps Ensure Physicians Can Access Critical Patient ... From the floor of the HIMSS09 Annual ... MDRX ) today introduced Allscripts Remote(TM), a ... virtually anytime, anywhere access to and control ...
Cached Medicine News:Health News:Cord Blood Announces $1.75 Million Reduction in Long Term Debt 2Health News:Marine Corps Launches Inaugural Marine Week in Chicago, May 11-17 2Health News:Marine Corps Launches Inaugural Marine Week in Chicago, May 11-17 3Health News:FFF Named the Exclusive Distributor of Fluzone for GPOs & Announces New Fluzone Return Policy 2Health News:Arthritis Trial Leads to Potential Cure for High Blood Pressure 2Health News:Spotlight Baby Provides Parents with Educational Programs and Eco-Friendly Products to Support Babies in Reaching Their Full Developmental Potentials 2Health News:Allscripts Introduces Electronic Health Record Capability for iPhone(TM) 2Health News:Allscripts Introduces Electronic Health Record Capability for iPhone(TM) 3Health News:Allscripts Introduces Electronic Health Record Capability for iPhone(TM) 4Health News:Allscripts Introduces Electronic Health Record Capability for iPhone(TM) 5
The Oxoid Legionella Latex Test is a latex agglutination test for the identification of predominant Legionella species grown on plate media from patients with suspected Legionellosis or from environm...
... A revolutionary new agar plate for economically screening ... this biplate with the urine specimen. If the ... the chromogenic side of the biplate will 3 ... E. coli, the BluEcoli™ Urine Biplate is a ...
... The Trinity Biotech Captia™ Legionella ... (ELISA) is intended for the ... (IgG and IgM) to Legionella ... serum from patients with clinical ...
SDA is a patented isothermal amplification technology capable of generating billions of copies of target molecules from a single DNA or RNA template in just minutes....
Medicine Products: